 Home > Active Ingredient News > Drugs Articles > The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved in China

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved in China

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

anti rnp antibody

turban tumor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 11, Kaifeng Pharmaceutical announced that the clinical trial of ALK-1 monoclonal antibody (GT90001C) combined with Nivolumab has been approved by the China National Medical Products Administration on October 9 for use in advanced hepatocytes without systemic treatment.
Cancer (HCC) patients
.

ALK-1 monoclonal antibody is a fully human monoclonal antibody that can inhibit ALK-1/TGF-β signal transduction and tumor angiogenesis.
It is a potential first-in-class anti-angiogenesis inhibitor
.

The company obtained the exclusive global development, production and commercialization rights of the drug from Pfizer in 2018

The Phase II clinical trial (NCT03893695) of ALK-1 monoclonal antibody combined with Nivolumab for advanced HCC patients who progressed after treatment with rafenib or lenvatinib was first launched in Taiwan, China on May 7, 2019
.

On January 17, 2021, the positive data of the Taiwanese clinical trial announced by the company at the 2021 American Society of Clinical Oncology Gastrointestinal Tumor Symposium (ASCO GI 2021) showed that the efficacy of the combination therapy is encouraging and the safety is good.

On February 11, 2021, the Phase II clinical trial of ALK-1 monoclonal antibody combined with Nivolumab for the treatment of HCC was approved by the US FDA

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China

11-05

Related Products

Best Price Isopropylbenzylamine Crystal CAS 102-97-6 N-Isopropylbenzylamine Fast Delivery 99% crystal chemicals

CAS No.: 102-97-6

Pharmacy Grade

$2-2.2/MT EXW

Pregabalin Crystal CAS 148553-50-8 Lyrica Powder 99.0% White Powder Mobelbiochem

CAS No.: 148553-50-8

Pharmacy Grade

$35.00/KG FOB

PTD-DBM 99% freeze dried powder cas1199495-15-2

CAS No.: 1199495-15-2

Pharmacy Grade

$3-3.2/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved in China

Related Articles

The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O drug by Kaixing Pharmaceutical was approved in China